Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Biothreat Antibiotic Susceptibility Testing with Biomerieux’s EasyMag

by Global Biodefense Staff
July 31, 2013

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick has issued a solicitation for Antibiotic Susceptibility Strips and EasyMag System Reagents that determine the quantitative antibiotic susceptibility of biothreat agents.

Previously established USAMRIID protocols require bacterium be grown on agar plates in the presence of antibiotic e-strips coated with antibiotic gradients and marked with quantitative tick marks for measuring the zone of clearing.  This requirement is for brand name or equal EasyMag system reagents, consumables, controls, calibrators, and parts on an as-needed basis. 

“The Biomerieux EasyMag is an automated nucleic acid extraction platform used by our division,” states the announcement. “The system is integrated into an ongoing funded study for both platform evaluation and support of mission essential sample processing.”

The following are the Minimal Essential Characteristics for the EasyMag sample prep reagents to be procured:

  • Must be Biomerieux brand name or equivalent
  • Must be available for all 44 antibiotics requested
  • Must be packaged in 30 strip per package format
  • Must contain clearly labeled gradient tick marks of antibiotic concentration
  • Must provide 15 dilutions per strip
  • Must have antibiotic abbreviation written on top of Estrip
  • Must have expiration date no less than 1.5 years from time of order 

Under the contract, USAMRIID places an order as required, and the vendor delivers as early as the next business day but no later than 5 business days. The Period of Performance is a twelve-month base year with four twelve-month options years. 

Source: FBO.gov

Editor’s Note: While the acquisition of laboratory equipment or reagents is commonplace, we periodically cover these activities for insight into the research, acquisition and mission priorities of biodefense-relevant organizations.

Tags: AntimicrobialsUSAMRIID

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy